DK2685995T3 - Immunterapeutiske gær-brachyury-sammensætninger - Google Patents

Immunterapeutiske gær-brachyury-sammensætninger Download PDF

Info

Publication number
DK2685995T3
DK2685995T3 DK12757534.8T DK12757534T DK2685995T3 DK 2685995 T3 DK2685995 T3 DK 2685995T3 DK 12757534 T DK12757534 T DK 12757534T DK 2685995 T3 DK2685995 T3 DK 2685995T3
Authority
DK
Denmark
Prior art keywords
brachyury
yeast
ser
seq
pro
Prior art date
Application number
DK12757534.8T
Other languages
English (en)
Inventor
Claudia Palena
Zhimin Guo
David Apelian
Jeffrey Schlom
Original Assignee
Globeimmune Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc, Us Health filed Critical Globeimmune Inc
Application granted granted Critical
Publication of DK2685995T3 publication Critical patent/DK2685995T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)

Claims (30)

1. Immunterapeutisk sammensætning omfattende: a) en gærvehikel; og b) et cancerantigen omfattende mindst ét Brachyury-antigen, til anvendelse i en fremgangsmåde til at reducere, standse, reversere, forsinke eller forebygge metastatisk progression af cancer hos en person, som har cancer.
2. Immunterapeutisk sammensætning til anvendelse ifølge krav 1, hvor Brachyury-ekspression ikke er detekteret i personens cancer på det tidspunkt, hvor sammensætningen indgives første gang.
3. Immunterapeutisk sammensætning til anvendelse ifølge krav 1, hvor Brachyury-ekspression er detekteret i personens cancer på det tidspunkt, hvor sammensætningen indgives første gang.
4. Immunterapeutisk sammensætning til anvendelse ifølge krav 1, hvor personen har stadium l-cancer, har stadium Il-cancer, har stadium lll-cancer eller har stadium IV-cancer.
5. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor personen behandles eller er blevet behandlet med en anden terapi mod cancer.
6. Immunterapeutisk sammensætning til anvendelse ifølge krav 5, hvor terapien er kemoterapi, målrettet cancerterapi, strålebehandling, adoptiv T-celle-overførsel eller kirurgisk resektion af en tumor fra personen.
7. Immunterapeutisk sammensætning til anvendelse ifølge krav 5, hvor terapien er indgivelse af en eller flere yderligere immunterapeutiske sammensætninger.
8. Immunterapeutisk sammensætning til anvendelse ifølge krav 7, hvor de yderligere immunterapeutiske sammensætninger omfatter en gærvehikel og et andet cancerantigen, der ikke indbefatter Brachyury-antigen.
9. Immunterapeutisk sammensætning til anvendelse ifølge krav 8, hvor det andet cancerantigen er udvalgt fra gruppen bestående af: muteret Ras, car-cinoembryonalt antigen (CEA), MUC-1, EGFR, BCR-Abl, MART-1, MAGE-1, MAGE-3, GAGE, GP-100, MUC-2, PSMA, tyrosinase, TRP-1 (gp75), NY-ESO-1, TRP-2, TAG72, KSA, CA-125, PSA, HER-2/neu/c-erbB2, hTERT, p73, B-RAF, adenomatøs polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL), Rb-1, Rb-2, androgenreceptor (AR), Smad4, MDR1, Flt-3, BRCA-1, BRCA-2, pax3-fkhr, ews-fli-1, FIERV-H, HERV-K, TWIST, mesothelin og NGEP.
10. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor canceren er udvalgt fra gruppen bestående af: brystcancer, cancer i tyndtarmen, mavecancer, pancreascancer, nyrecancer, blærecancer, livmoderkræft, æggestokkræft, testi kel kræft, lungecancer, co-loncancer, prostatacancer, kronisk lymfatisk leukæmi (CLL), Epstein-Barr-virus-transformerede B-celler, Burkitts lymfom, Hodgkins lymfom og metasta-tiske cancere deraf.
11. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor Brachyury-antigenet har en aminosyresekvens, der er repræsenteret af SEQ ID NO: 18, SEQ ID NO:6 eller SEQ ID NO:2, eller en aminosyresekvens, der er mindst 85 % identisk med SEQ ID NO:18, SEQ ID NO:6 eller SEQ ID NO:2.
12. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor Brachyury-antigenet har en aminosyresekvens, der er repræsenteret af SEQ ID NO: 18, SEQ ID NO:6 eller SEQ ID NO:2, eller en aminosyresekvens, der er mindst 90 % identisk med SEQ ID NO: 18, SEQ ID NO:6 eller SEQ ID NO:2.
13. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor Brachyury-antigenet har en aminosyresekvens, der er repræsenteret af SEQ ID NO: 18, SEQ ID NO:6 eller SEQ ID NO:2, eller en aminosyresekvens, der er mindst 95 % identisk med SEQ ID NO:18, SEQ ID N0:6 eller SEQ ID N0:2.
14. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor Brachyury-antigenet omfatter position 246 til 254 af SEQ ID NO: 18, SEQ ID NO:6 eller SEQ ID NO:2.
15. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor Brachyury-antigenet omfatter position 246 til 254 af SEQ ID NO: 18.
16. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor Brachyury-antigenet omfatter en substitution af et leucin ved position 254 med et valin af SEQ ID NO: 18.
17. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor Brachyury-antigenet omfatter SEQ ID NO:18, position 2-435 af SEQ ID NO:18, en aminosyresekvens, der er mindst 85 % identisk med SEQ ID NO:18, SEQ ID NO:6, position 2-435 af SEQ ID NO:6, en aminosyresekvens, der er mindst 85 % identisk med SEQ ID NO:6, SEQ ID NO:2, position 2-435 af SEQ ID NO:2 eller en aminosyresekvens, der er mindst 85 % identisk med SEQ ID NO:2.
18. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor Brachyury-antigenet omfatter en aminosyresekvens, der er mindst 99 % identisk med SEQ ID NO: 18, mindst 99 % identisk med SEQ ID NO:6 eller mindst 99 % identisk med SEQ ID NO:2.
19. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 18, hvor cancerantigenet er et fusionsprotein med en aminosyresekvens, der er repræsenteret af SEQ ID NO:8, SEQ ID NO:20 eller en aminosyresekvens, der er mindst 95 % identisk med SEQ ID NO:8 eller SEQ ID NO:20.
20. Immunterapeutisk sammensætning til anvendelse ifølge krav 19, hvor ekspression af fusionsproteinet er under styring af promoteren CUP1.
21. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 20, hvor gærvehiklen er en dræbt hel gær.
22. Immunterapeutisk sammensætning til anvendelse ifølge krav 21, hvor den hele gær er varmeinaktiveret.
23. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 22, hvor gærvehiklen udtrykker antigenet.
24. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 23, hvor gæren er fra Saccharomyces cerevisiae.
25. Immunterapeutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 24, hvor sammensætningen er formuleret i en farmaceutisk acceptabel excipiens, der er egnet til indgivelse til et individ.
26. Immunterapeutisk gær-Brachyury-sammensætning, hvor den immunterapeutiske sammensætning omfatter: a) en gærvehikel; b) et antigen udtrykt af gærvehiklen og omfattende mindst ét Brachyury-antigen, hvor Brachyury-antigenet omfatter en aminosyresekvens, der er mindst 85 % identisk med SEQ ID NO:18 og indbefatter en substitution af et leucin ved position 254 med et valin; og c) en farmaceutisk acceptabel excipiens, der er egnet til indgivelse til et menneske.
27. Immunterapeutisk gær-Brachyury-sammensætning ifølge krav 26, hvor Brachyury-antigenet omfatter en aminosyresekvens, der er mindst 90 % identisk med SEQ ID SEQ ID NO: 18.
28. Immunterapeutisk gær-Brachyury-sammensætning ifølge krav 26, hvor Brachyury-antigenet omfatter en aminosyresekvens, der er mindst 95 % identisk med SEQ ID NO:18.
29. Immunterapeutisk gær-Brachyury-sammensætning ifølge krav 26, hvor Brachyury-antigenet omfatter position 2-435 af SEQ ID NO:18.
30. Immunterapeutisk gær-Brachyury-sammensætning ifølge krav 26 til 29 til anvendelse til behandling af en sygdom.
DK12757534.8T 2011-03-17 2012-03-19 Immunterapeutiske gær-brachyury-sammensætninger DK2685995T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453656P 2011-03-17 2011-03-17
PCT/US2012/029636 WO2012125998A1 (en) 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions

Publications (1)

Publication Number Publication Date
DK2685995T3 true DK2685995T3 (da) 2017-08-21

Family

ID=46831122

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12757534.8T DK2685995T3 (da) 2011-03-17 2012-03-19 Immunterapeutiske gær-brachyury-sammensætninger

Country Status (19)

Country Link
US (5) US9198941B2 (da)
EP (2) EP3238731B1 (da)
JP (4) JP6068368B2 (da)
KR (1) KR102046449B1 (da)
CN (1) CN103648513B (da)
AU (3) AU2012228937B2 (da)
BR (1) BR112013023456B1 (da)
CA (1) CA2835475C (da)
DK (1) DK2685995T3 (da)
ES (1) ES2627979T3 (da)
HK (1) HK1245649A1 (da)
HU (1) HUE033491T2 (da)
IL (1) IL228421B (da)
MX (1) MX350661B (da)
PL (1) PL2685995T3 (da)
PT (1) PT2685995T (da)
RU (2) RU2690180C2 (da)
SG (2) SG10201601913RA (da)
WO (1) WO2012125998A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EA028659B1 (ru) 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
BR112013032381B1 (pt) 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014043518A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
MX374829B (es) * 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
WO2017023840A1 (en) * 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
EP4137150A1 (en) * 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
CA3026342A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
US11571446B2 (en) 2016-11-18 2023-02-07 Sanford Bumham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
IL314202B1 (en) 2017-04-24 2026-04-01 Nantcell Inc Neoepitope vectors and methods for them
EP3668538A4 (en) * 2017-08-15 2021-06-16 NantCell, Inc. HANK-CETUXIMAB COMBINATIONS AND PROCEDURES
WO2019222073A1 (en) 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036329A (en) 1908-11-19 1912-08-20 Edison Inc Thomas A Phonograph-reproducer.
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR20080043775A (ko) 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
AU2008214029B2 (en) 2007-02-02 2014-01-30 Globelmmune, Inc. Methods for producing yeast-based vaccines
EP2125868B1 (en) 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2134358A1 (en) 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042642A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
KR101781966B1 (ko) * 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
WO2012019127A2 (en) * 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EA028659B1 (ru) 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
BR112013032381B1 (pt) 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도

Also Published As

Publication number Publication date
AU2012228937B2 (en) 2016-11-03
CA2835475C (en) 2020-06-30
AU2018202972A1 (en) 2018-05-17
ES2627979T3 (es) 2017-08-01
RU2619850C2 (ru) 2017-05-18
US20140004135A1 (en) 2014-01-02
SG193396A1 (en) 2013-10-30
CA2835475A1 (en) 2012-09-20
US20160106824A1 (en) 2016-04-21
US9623097B2 (en) 2017-04-18
JP2014509595A (ja) 2014-04-21
KR102046449B1 (ko) 2019-11-19
RU2690180C2 (ru) 2019-05-31
EP2685995B1 (en) 2017-05-03
RU2017116350A (ru) 2018-10-17
SG10201601913RA (en) 2016-05-30
AU2018202972B2 (en) 2019-08-29
JP6068368B2 (ja) 2017-01-25
MX2013010475A (es) 2014-05-28
US9198941B2 (en) 2015-12-01
JP2018090634A (ja) 2018-06-14
US10363294B2 (en) 2019-07-30
AU2017200715A1 (en) 2017-02-23
EP2685995A4 (en) 2014-12-24
US20190374624A1 (en) 2019-12-12
HK1245649A1 (en) 2018-08-31
RU2017116350A3 (da) 2018-10-17
IL228421B (en) 2019-02-28
BR112013023456B1 (pt) 2020-11-17
PL2685995T3 (pl) 2017-10-31
AU2012228937A1 (en) 2013-10-31
US11944673B2 (en) 2024-04-02
AU2017200715B2 (en) 2018-05-31
EP3238731A1 (en) 2017-11-01
IL228421A0 (en) 2013-12-31
PT2685995T (pt) 2017-08-09
JP2019199484A (ja) 2019-11-21
US20170246276A1 (en) 2017-08-31
US20210106666A1 (en) 2021-04-15
EP2685995A1 (en) 2014-01-22
CN103648513A (zh) 2014-03-19
WO2012125998A1 (en) 2012-09-20
KR20140038387A (ko) 2014-03-28
MX350661B (es) 2017-09-13
CN103648513B (zh) 2018-10-12
JP6580733B2 (ja) 2019-09-25
EP3238731B1 (en) 2021-02-17
RU2013146324A (ru) 2015-04-27
BR112013023456A2 (pt) 2016-12-06
NZ616696A (en) 2015-09-25
US11938175B2 (en) 2024-03-26
HUE033491T2 (en) 2017-12-28
JP6309607B2 (ja) 2018-04-11
JP2017061570A (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
US11938175B2 (en) Yeast-brachyury immunotherapeutic compositions
WO2017023840A1 (en) Modified yeast-brachyury immunotherapeutic compositions
HK1192141A (en) Yeast-brachyury immunotherapeutic compositions
HK1192141B (en) Yeast-brachyury immunotherapeutic compositions
NZ724797B2 (en) Yeast-brachyury immunotherapeutic compositions
NZ616696B2 (en) Yeast-brachyury immunotherapeutic compositions
NZ724797A (en) Yeast-brachyury immunotherapeutic compositions
NZ711188A (en) Yeast-brachyury immunotherapeutic compositions
NZ711188B2 (en) Yeast-brachyury immunotherapeutic compositions